A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults

Dialysis Clinical Trial

Official title:

A Pilot, Observation and Feasibility Study of Prevora (DIN 02046245) Integrated Into Homecare Visits of Adults With COPD or CHF or on Dialysis or Other Chronic Metabolic Conditions Which Are Correlated With Chronic Oral Inflammation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06158633
• Other study ID #: CHX2023-002
• Status: Not yet recruiting
• Start date: December 2023
• Est. completion date: October 2024

Study information

• Verified date: December 2023
• Source: CHX Technologies Inc.
• Contact: Suzana Damjanovic
• Phone: 365-833-8140
• Email: DentalStudy[@]stjoes.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria. Prevora is applied to the teeth and gumline by a medical professional, takes about 10 minutes and is painless. Participating site(s) have a homecare program and usual care includes offering patients home care services before discharge from the hospital for some chronic diseases. Usual care includes home visits by a nurse and or personal support worker (PSW). The aim of this study is to explore the effectiveness, health benefits and feasibility of delivering preventive oral healthcare with Prevora, during a homecare visit by a nurse or PSW. All consenting and eligible subjects will continue with their usual care with the homecare program. The study is 5 months long. Subjects will have a Prevora treatment applied by the homecare nurse or PSW on Day 1, 14 days, 3 months and 4 months. The study includes several follow up visits which will be conducted in the patient's home and or by telephone or videoconferencing if needed. Oral exams, lab tests and subject completed questionnaires will be collected for the study. Changes in medications and any possible side effects will also be monitored during the study.

Description:

Poor oral health and specifically, inflammation of the gums is linked to respiratory problems, heart problems and inflammation through the body. Worsening oral health and inflammation of the gums occurs often in patients with chronic diseases who are hospitalized and often continues after discharge from the hospital. This can make health recovery more difficult for the patient. This is a 5 month, prospective, single-arm, open-label, observational and feasibility, phase IV trial evaluating the efficacy and safety of Prevora and is focused on the integration of a preventive oral healthcare service into a hospital-based home healthcare program involving high-risk adults with COPD or CHF or on dialysis, and possibly other chronic metabolic conditions, which make the patient suitable for entry into a home care program. This study will be centrally coordinated by the Research Institute at St Joes and conducted in the homes of consenting and eligible participants in the greater Hamilton, Ontario area. Approximately 30 subjects will be enrolled in the study which is defined as starting the investigational product. All subjects will continue to receive the usual care that is provided as part of the respective home care program. After signed consent is obtained, subject screening and eligibility assessments will begin. Once a subject is confirmed to be eligible for study participation, investigational product treatment applications and study visits will be scheduled starting with Day 1. Follow up visits will occur 14 days, 1, 3, 4 and 5 months after Day 1. A delegated and trained homecare nurse or PSW will apply the investigational product during the study visits conducted on day 1, day 14, 3 and 4 months. Study visits will be scheduled at the same time as a standard of care (SOC) home visit or as a study visit only, independent of a SOC home visit. Study visits include evaluation of study outcomes/endpoints, subject completed questionnaires and measuring compliance. Changes in medications and any possible side effects will also be monitored during the study. Data will be captured in the case report form (CRF). To qualify, men and women must be enrolled in the home healthcare services program. All participants will receive the study intervention (Prevora) and be followed for 5 months. This study aims to demonstrate that in subjects who receive home healthcare visits and have COPD and/or CHF or on dialysis, and with moderate to severe forms of chronic oral inflammation, the investigational product (Prevora) will significantly decrease oral inflammation over time.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: October 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age
• Enrollment in the homecare COPD/CHF program or who possibly have other medical conditions such as on dialysis or chronic metabolic condition (e.g. diabetes, hypertension) suitable for entry into the home care program
• Bleeding on probing at = 12 sites at Screening
• Minimum of 10 natural teeth
• Willing and able to provide informed consent as per International Conference on Harmonization - Good Clinical Practices Guidelines (ICH-GCP E6(R2)) and applicable regulations.

Exclusion Criteria:

• Currently smoking one or more cigarettes per day
• Patients with a prosthetic heart valve
• Active visual caries which, in the judgement of the investigators, could require surgical restoration or extraction, and referral to a dentist on an urgent basis
• Severe periodontal disease which, in the judgement of the investigators, could require surgery or a level of periodontal scaling such that participation in the study will be delayed
• Undergoing periodontal care by a dentist or hygienist which in the judgement of the investigators could confound the study results
• Known allergies to the ingredients of the study medications (chlorhexidine, Sumatra benzoin, ethanol and polymethylmethacrylate)
• Taking medications for periodontal conditions (e.g., Periostat, chlorhexidine rinse, PerioChip or Arestin).
• Uncontrolled seizure disorder
• A gag reflex
• Cancer that is in an active stage of treatment or has been treated with chemotherapy and/or radiation in the past year or in the next 12 months
• Behavioural disorders which in the judgement of the investigators threaten the patient's tolerance to treatment and participation in the study
• Involved in another drug trial
• Not able to complete subject reported, self-administered questionnaires or not able have a caregiver complete these questionnaires, or cannot fully understand all instructions in English

Related Conditions & MeSH terms

• Chronic Metabolic Disorder
• COPD (Chronic Obstructive Pulmonary Disease)
• Dialysis
• Heart Failure
• Lung Diseases, Obstructive
• Metabolic Diseases
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Prevora
Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant. All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
CHX Technologies Inc.	St. Joseph's Health System - Centre for Integrated Comprehensive Care, The Research Institute of St Joe's Hamilton

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidences of adverse events (AE)	To determine the safety profile of Prevora in high-risk adults with CHF or COPD or on dialysis in a home health care setting.	Month 0 to Month 5
Other	Incidences of serious adverse events (SAE)	To determine the safety profile of Prevora in high-risk adults with CHF or COPD or on dialysis in a home health care setting.	Month 0 to Month 5
Other	Number of subjects discontinuing investigational product due to AE/SAEs	To determine the tolerability profile of Prevora in high-risk adults with CHF or COPD or on dialysis in a home health care setting.	Month 0 to Month 5
Primary	Mean Score Change by Categories of Bleeding on Probing	To evaluate Prevora's ability to improve oral health in adults with COPD or CHF or on dialysis or with metabolic disorders correlated with chronic oral inflammation, who are receiving home healthcare services.	Month 0 to Month 5
Primary	Frequency Distribution Change of Study Participants by Categories of Bleeding on Probing	To evaluate Prevora's ability to improve oral health in adults with COPD or CHF or on dialysis or with metabolic disorders correlated with chronic oral inflammation, who are receiving home healthcare services.	Month 0 to Month 5
Secondary	Mean Score Change by Categories of Pocket Probing Depth	To further evaluate Prevora's ability to improve oral health in adults with COPD or CHF or on dialysis or with chronic metabolic disorders correlated with chronic oral inflammation, who are receiving home healthcare services.	Month 0 to Month 5
Secondary	Frequency Distribution Change of Study Participants by Categories of Pocket Probing Depth	To further evaluate Prevora's ability to improve oral health in adults with COPD or CHF or on dialysis or with chronic metabolic disorders correlated with chronic oral inflammation, who are receiving home healthcare services.	Month 0 to Month 5
Secondary	Change in Number of Decayed, Missing and Filled Teeth	To assess the oral health status of study participants by way of an oral health examination conducted by a mobile independent hygienist in the home.	Month 0 to Month 5
Secondary	Change in Number of Teeth with Active Cavitated Lesions	To assess the oral health status of study participants by way of an oral health examination conducted by a mobile independent hygienist in the home.	Month 0 to Month 5
Secondary	Change in Level of Xerostomia	To assess the oral health status of study participants by way of an oral health examination conducted by a mobile independent hygienist in the home.	Month 0 to Month 5
Secondary	Mean Score Change in hsCRP (high sensitivity C-reactive protein)	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Change in Frequency Distribution of hsCRP (high sensitivity C-reactive protein)	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Mean Score Change in ESR (Erythrocyte Sedimentation Rate)	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Change in Frequency Distribution of ESR (Erythrocyte Sedimentation Rate)	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Mean Score Change in Cholesterol	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Change in Frequency Distribution of Cholesterol	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Mean Score Change in Blood Glucose	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Change in Frequency Distribution of Blood Glucose	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Mean Score Change in HbA1c	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Change in Frequency Distribution of HbA1c	To evaluate Prevora's ability to change blood-based markers of inflammation.	Month 0 to Month 5
Secondary	Change in Mean Scores of Subject Self-Reported Shortness of Breath using a Visual Analogue Scale in Chronic Obstructive Pulmonary Disease participants only.	To evaluate Prevora's effect on self reported shortness of breath in COPD participants.; Scale title: Visual Analogue Scale Assessment for Degree of Breathlessness Minimum Value: 0 Maximum Value: 100 Higher Score equals a worse outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Frequency Distribution of Subject Self-Reported Shortness of Breath using a Visual Analogue Scale in Chronic Obstructive Pulmonary Disease participants only.	To evaluate Prevora's effect on self reported shortness of breath in COPD participants.; Scale title: Visual Analogue Scale Assessment for Degree of Breathlessness Minimum Value: 0 Maximum Value: 100 Higher Score equals a worse outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Mean Scores of Subject Self-Reported Ankle Swelling using a Visual Analogue Scale in Congestive Heart Failure subjects only.	To evaluate Prevora's effect on self reported ankle swelling in CHF participants.; Scale title: Visual Analogue Scale Assessment for Degree of Ankle Swelling Minimum Value: 0 Maximum Value: 100 Higher Score equals a worse outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Frequency Distribution of Subject Self-Reported Ankle Swelling using a Visual Analogue Scale in Congestive Heart Failure subjects only.	To evaluate Prevora's effect on self reported ankle swelling in CHF participants.; Scale title: Visual Analogue Scale Assessment for Degree of Ankle Swelling Minimum Value: 0 Maximum Value: 100 Higher Score equals a worse outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Mean Scores of Subject Self-Reported Fatigue using a Visual Analogue Scale in Congestive Heart Failure subjects only.	To evaluate Prevora's effect on self reported fatigue in CHF participants. Scale title: Visual Analogue Scale Assessment for Degree of Fatigue Minimum Value: 0 Maximum Value: 100 Higher Score equals a worse outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Frequency Distribution of Subject Self-Reported Fatigue using a Visual Analogue Scale in Congestive Heart Failure subjects only.	To evaluate Prevora's effect on self reported fatigue in CHF participants. Scale title: Visual Analogue Scale Assessment for Degree of Fatigue Minimum Value: 0 Maximum Value: 100 Higher Score equals a worse outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Mean Scores of Subject Self-Reported Energy Level using a Visual Analogue Scale in subjects on dialysis only	To evaluate Prevora's effect on self reported energy level in participants on dialysis.; Scale title: Visual Analogue Scale Assessment of Energy Levels Minimum Value: 0 Maximum Value: 100 Higher Score equals a better outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Change in Frequency Distribution of Subject Self-Reported Energy Level using a Visual Analogue Scale in subjects on dialysis only.	To evaluate Prevora's effect on self reported energy level in participants on dialysis.; Scale title: Visual Analogue Scale Assessment of Energy Levels Minimum Value: 0 Maximum Value: 100 Higher Score equals a better outcome	Month 0, Day 1, 14 days, Month 3, 4 and 5
Secondary	Subject Self-Reported Tolerance to Study Intervention measured using a Visual Analogue Scale in all subjects Scale title: Visual Analogue Scale Assessment Acceptability Minimum Value: 0 Maximum Value: 100 Higher Score equals a better outcome	To evaluate qualitative measures of Prevora's treatment effect in terms of a survey of participants for tolerability to treatment.; Scale title: Visual Analogue Scale Assessment Acceptability Minimum Value: 0 Maximum Value: 100 Higher Score equals a better outcome	Month 5 only
Secondary	Subject Self-Reported General Well-being measured using a Visual Analogue Scale in all subjects	To evaluate qualitative measures of Prevora's treatment effect in terms of a survey of participants for general well-being.; Scale title: Visual Analogue Scale Assessment of Importance of Treatment Minimum Value: 0 Maximum Value: 100 Higher Score equals a better outcome	Month 5 only
Secondary	Subject Self-Reported Willingness to Continue Study Intervention, measured using a Visual Analogue Scale in all subjects	To evaluate qualitative measures of Prevora's treatment effect in terms of a survey of participants for willingness to continue treatment.; Scale title: Visual Analogue Scale Assessment of Willingness to Continue Treatment Post-Study Minimum Value: 0 Maximum Value: 100 Higher Score equals a better outcome	Month 5 only
Secondary	Mean time to administer Prevora by homecare provider	To evaluate the feasibility of integrating preventive oral health services into a home healthcare program, including training of the homecare provider, logistics, costs, and revenues so as to define best practices for integration.	Day 1, 14 days, Months 3 and 4
Secondary	Adequacy, comprehension, competence and confidence of the homecare provider as measured by survey	To evaluate the feasibility of integrating preventive oral health services into a home healthcare program, including training of the homecare provider, logistics, costs, and revenues so as to define best practices for integration. Study intervention is applied by homecare providers. This survey is completed by homecare provider, not participants.	At end of study or when homecare provider ends involvement with study
Secondary	Logistics of administering Prevora in the home as measured by survey	To evaluate the feasibility of integrating preventive oral health services into a home healthcare program, including training of the homecare provider, logistics, costs, and revenues so as to define best practices for integration. Study intervention is applied by homecare providers. This questionnaire is completed by homecare provider(s), not participants.	At end of study or when homecare provider ends involvement with study
Secondary	Percentage of subjects who are adherent to Prevora treatment regimen	To determine adherence or compliance to investigational product.	Day 1 to Month 4